Template:Metoprolol: Difference between revisions

Metoprolol
Clinical data
Trade names	Lopressor, Toprol-xl
AHFS/Drugs.com	Monograph
MedlinePlus	a682864
[[Regulation of therapeutic goods \|Template:Engvar data]]	US FDA: Metoprolol;
Pregnancy; category	AU: C ; US: C (Risk not ruled out) ; ;
Routes of; administration	Oral, IV
ATC code	C07AB02 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	12%
Metabolism	Hepatic via CYP2D6, CYP3A4
Elimination half-life	3-7 hours
Excretion	Renal
Identifiers
	IUPAC name (RS)-1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol;
CAS Number	51384-51-1 ;
PubChem CID	4171;
IUPHAR/BPS	553;
DrugBank	DB00264 ;
ChemSpider	4027 ;
UNII	GEB06NHM23;
KEGG	D02358 ;
ChEBI	CHEBI:6904 ;
ChEMBL	ChEMBL13 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H25NO3
Molar mass	267.364 g/mol
3D model (JSmol)	Interactive image;
Melting point	120 °C (248 °F)
	SMILES O(c1ccc(cc1)CCOC)CC(O)CNC(C)C;
	InChI InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3 ; Key:IUBSYMUCCVWXPE-UHFFFAOYSA-N ;
(verify)

VisualWikitext

Latest revision as of 15:36, 21 March 2014

@@ Line 1: / Line 1: @@
-{| class="infobox" style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width: 250px;" cellpadding="0" cellspacing="0";
+{{Drugbox
-! style="padding: 0 5px; font-size: 100%; background:#F8F8FF;" align=center | [[Metoprolol|{{fontcolor|#2B3B44|Metoprolol}}]]
+| verifiedrevid = 459444186
-|-
+| IUPAC_name = (''RS'')-1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
-! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [[Lopressor|{{fontcolor|#2B3B44|Lopressor (metoprolol tartrate) tablet}}]]
+| image = 2000px-Metoprolol structure.svg.png
-|-
+| drug_name = Metoprolol
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor indications and usage|Indications and Usage]]
-|-
+<!--Clinical data-->
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor dosage and administration|Dosage and Administration]]
+| tradename = Lopressor, Toprol-xl
-|-
+| Drugs.com = {{drugs.com|monograph|metoprolol-succinate}}
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor dosage forms and strengths|Dosage Forms and Strengths]]
+| MedlinePlus = a682864
-|-
+| licence_US = Metoprolol
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor contraindications|Contraindications]]
+| pregnancy_AU = C
-|-
+| pregnancy_US = C
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor warnings and precautions|Warnings and Precautions]]
+| legal_status = Rx-only
-|-
+| routes_of_administration = Oral, [[Intravenous|IV]]
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor adverse reactions|Adverse Reactions]]
-|-
+<!--Pharmacokinetic data-->
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor drug interactions|Drug Interactions]]
+| bioavailability = 12%
-|-
+| metabolism = [[Liver|Hepatic]] via [[CYP2D6]], [[CYP3A4]]
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor use in specific populations|Use in Specific Populations]]
+| elimination_half-life = 3-7 hours
-|-
+| excretion = [[Kidney|Renal]]
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor overdosage|Overdosage]]
-|-
+<!--Identifiers-->
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor description|Description]]
+| CAS_number_Ref = {{cascite|correct|??}}
-|-
+| CAS_number = 51384-51-1
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical pharmacology|Clinical Pharmacology]]
+| ATC_prefix = C07
-|-
+| ATC_suffix = AB02
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor nonclinical toxicology|Nonclinical Toxicology]]
+| PubChem = 4171
-|-
+| IUPHAR_ligand = 553
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical studies|Clinical Studies]]
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-|-
+| DrugBank = DB00264
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor how supplied storage and handling|How Supplied/Storage and Handling]]
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
-|-
+| ChemSpiderID = 4027
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor patient counseling information|Patient Counseling Information]]
+| UNII_Ref = {{fdacite|correct|FDA}}
-|-
+| UNII = GEB06NHM23
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor labels and packages|Labels and Packages]]
+| KEGG_Ref = {{keggcite|correct|kegg}}
-|-
+| KEGG = D02358
-! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [[Toprol XL|{{fontcolor|#2B3B44|Toprol XL (metoprolol succinate) tablet, extended release}}]]
+| ChEBI_Ref = {{ebicite|correct|EBI}}
-|-
+| ChEBI = 6904
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL indications and usage|Indications and Usage]]
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
-|-
+| ChEMBL = 13
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL dosage and administration|Dosage and Administration]]
-|-
+<!--Chemical data-->
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL dosage forms and strengths|Dosage Forms and Strengths]]
+| C=15 | H=25 | N=1 | O=3
-|-
+| molecular_weight = 267.364&nbsp;[[gram|g]]/[[Mole (unit)|mol]]
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL contraindications|Contraindications]]
+| smiles = O(c1ccc(cc1)CCOC)CC(O)CNC(C)C
-|-
+| InChI = 1/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL warnings and precautions|Warnings and Precautions]]
+| InChIKey = IUBSYMUCCVWXPE-UHFFFAOYAN
-|-
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL adverse reactions|Adverse Reactions]]
+| StdInChI = 1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
-|-
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL drug interactions|Drug Interactions]]
+| StdInChIKey = IUBSYMUCCVWXPE-UHFFFAOYSA-N
-|-
+| melting_point = 120
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL use in specific populations|Use in Specific Populations]]
+}}
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL overdosage|Overdosage]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL description|Description]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical pharmacology|Clinical Pharmacology]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL nonclinical toxicology|Nonclinical Toxicology]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical studies|Clinical Studies]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL how supplied storage and handling|How Supplied/Storage and Handling]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL patient counseling information|Patient Counseling Information]]
-|-
-! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL labels and packages|Labels and Packages]]
-|-
-! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [[Metoprolol (patient information)|{{fontcolor|#2B3B44|Patient Information}}]]
-|-
-! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}  {{fontcolor|#2B3B44|Clinical Trials}}]
-|-
-|}

Template:Metoprolol: Difference between revisions

Latest revision as of 15:36, 21 March 2014

Navigation menu